Development of CytoRisk score and validation. (A) Initial 2-point preinfusion system. (B) Initial 5-point preinfusion and postinfusion system. (C) Validation receiver operating characteristic (ROC) curves for initial 2-point preinfusion, initial 5-point preinfusion and postinfusion, and CAR-HEMATOTOX systems. ∗For all risk scores, the AUC was significantly different from 0.50 (P < .001). (D) Optimized 4-point preinfusion system. (E) Optimized 7-point preinfusion and postinfusion system. (F) Validation ROC curves for optimized 4-point preinfusion, optimized 7-point preinfusion and postinfusion, and CAR-HEMATOTOX systems. ∗For all risk scores, the AUC was significantly different from 0.50 (P < .001). (G) Prediction performance for all candidate systems at the respective proposed threshold for high risk.